1 Regular Article

12 13 14

15

16

17 18 19

20

21

22

23 24

25

26

27

28 29

30 31 32

33 34

35

36

37

38

- 2 3 Number of Words: 4,866
- 4 Number of Figures: 3
- 5 Number of Tables: 36 Supplementary Tables: 2
  - Christianson Syndrome across the Lifespan:

# An International Longitudinal Study in Children, Adolescents, and Adults

Brian C. Kavanaugh<sup>1,2</sup>, Jennifer Elacio<sup>1,2,3</sup>, Carrie R. Best<sup>1,2,3</sup>, Danielle G. St. Pierre<sup>1,2,3</sup>, Matthew F. Pescosolido<sup>1,2,3</sup>, Qing Ouyang<sup>1,2,3</sup>, Paul Caruso<sup>4</sup>, Karen Buch<sup>5</sup>, John Biedermann<sup>1,2,3</sup>, Rebecca S. Bradley<sup>1,2</sup>, Judy S. Liu<sup>1,2,3,6</sup>, Richard N. Jones<sup>7</sup> and Eric M. Morrow<sup>1,2,3#</sup>

 <sup>1</sup>Developmental Disorders Genetics Research Program, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, and Emma Pendleton Bradley Hospital, East Providence, RI, USA;
 <sup>2</sup>Center for Translational Neuroscience, Robert J. and Nancy D. Carney Institute for Brain Science and Brown Institute for Translational Science, Brown University, Providence, RI, USA;
 <sup>3</sup>Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA;

<sup>3</sup>Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA; <sup>4</sup>Lenox Hill Radiology, New York, NY 10075;

<sup>5</sup>Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114; <sup>6</sup>Department of Neurology, Rhode Island Hospital, Providence, RI 02903;

<sup>7</sup>Quantitative Sciences Program, Department of Psychiatry and Human Behavior and Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA

Running title: CS across the lifespan

 \*To whom correspondence should be addressed: Eric M. Morrow MD PhD
 Brown University, Lab for Molecular Medicine, 70 Ship Street, Providence, RI 02912 Tel: 401-863-9778
 Fax: 401- 432-1607
 E-mail: <u>eric\_morrow@brown.edu</u>

### 39 ABSTRACT

Mutations in the X-linked endosomal Na+/H+ Exchanger 6 (NHE6) causes Christianson Syndrome (CS). In the 40 largest study to date, we examine genetic diversity and clinical progression, including cerebellar degeneration, 41 in CS into adulthood. Data were collected as part of the International Christianson Syndrome and NHE6 42 (SLC9A6) Gene Network Study. Forty-four individuals with 31 unique NHE6 mutations, age 2 to 32 years, were 43 followed prospectively, herein reporting baseline, 1-year follow-up, and retrospective natural history. We 44 present data on the CS phenotype with regard to physical growth, adaptive and motor regression, and across 45 the lifespan, including information on mortality. Longitudinal data on body weight and height were examined 46 using a linear mixed model; the rate of growth across development was slow and resulted in prominently 47 decreased age-normed height and weight by adulthood. Adaptive functioning was longitudinally examined: a 48 49 majority of adult (18+ years) participants lost gross and fine motor skills over a 1-year follow-up. Previously defined core diagnostic criteria for CS (present in >85%) – namely nonverbal status, intellectual disability, 50 epilepsy, postnatal microcephaly, ataxia, hyperkinesia – were universally present in age 6 to 16; however, an 51 additional core feature of high pain tolerance was added (present in 91%), and furthermore, evolution of 52 symptoms were noted across the lifespan, such that postnatal microcephaly, ataxia and high pain threshold 53 54 were often not apparent prior to age 6, and hyperkinesis decreased after age 16. While neurologic exams were consistent with cerebellar dysfunction, importantly, a majority of individuals (>50% older than 10) also had 55 56 corticospinal tract abnormalities. Three participants died during the period of the study. In this large and longitudinal study of CS, we begin to define the trajectory of symptoms and the adult phenotype, thereby 57 identifying critical targets for treatment. 58

Key words: Christianson Syndrome, Neurodevelopment; Neurodegeneration; Endosome; Cerebellum;
Regression

### 61 **INTRODUCTION**

Christianson syndrome (CS) in males results from loss-of-function (LOF) mutations in the X-linked gene 62 SLC9A6 which encodes the endosomal Na+/H+ Exchanger 6 (NHE6).<sup>1-4</sup> CS is one of the most common forms 63 of X-linked intellectual disability.<sup>5</sup> The NHE6 protein modulates intra-endosomal pH and endosomal 64 maturation.<sup>6,7</sup> Studies of the pathophysiology of CS in animals and cells lacking NHE6 have identified both 65 neurodevelopmental and neurodegenerative features.<sup>6,8-11</sup> In male patients, CS presents early with global 66 67 developmental delay, lack of language, postnatal microcephaly, ataxia, epilepsy, and Angelman Syndrome-like and/or autistic features.<sup>1</sup> However, little systematic data exists which establishes the life course of symptoms in 68 people with CS into adulthood. In addition to abnormal brain development, progressive neurodegenerative and 69 medical processes unfold with age.<sup>1,12</sup> Accordingly, CS has been conceptualized as a mixed 70 neurodevelopmental and neurodegenerative disorder.<sup>10</sup> 71

In the initial large pedigree, Dr. Arnold Christianson and colleagues reported that early neurodevelopmental 72 abnormalities were followed by a "slow regression" starting in the second decade of life.<sup>3</sup> In our prior report of 73 74 14 CS probands, we identified a history of regression in 50% of participants.<sup>1</sup> Also, CS has been described to involve a progressively worsening ataxia, which appears to be associated with the high prevalence of 75 cerebellar degeneration in patients (atrophy in 30-60% of cases).<sup>1-4,13</sup> Further, human neuropathologic 76 studies<sup>3,12</sup> and NHE6-null mouse and rat models have identified cerebellar Purkinje cell loss, and as well as 77 cortical tissue loss, with tau deposition.<sup>8-10</sup> Dr. Christianson's original description of an extended South African 78 pedigree suggested progressive morbidity, thin body habitus, and a potential risk of early mortality<sup>3</sup>; however, 79 to date the risk of early mortality has not been corroborated in larger studies. 80

A range of different NHE6 mutations have been reported in CS. To date, the majority of published NHE6 81 mutations are nonsense or splice mutations that are thought to result in complete loss-of-function of the NHE6 82 protein.<sup>1-4</sup> Nonsense mutations appear to lead to nonsense mediated mRNA decay.<sup>14</sup> Other mutation types (for 83 example missense) have also been reported but are less common, yet may be informative to protein 84 function.<sup>1,15</sup> Mutations in CS males generally cluster in the Na<sup>+</sup>/H<sup>+</sup> exchanger region and are less commonly 85 found in the C-terminus cytoplasmic tail.<sup>1,2</sup> These cytoplasmic tail mutations, again particularly when missense, 86 could be highly informative given that the function of this part of the protein is not well understood. While 87 previously reported as inherited in pedigrees. de novo mutations now appear to be a relatively common form of 88

transmission.<sup>1</sup> Finally, Pescosolido et al.<sup>1</sup> found little genotype-phenotype correlations between specific

90 mutations, although the sample size was limiting for this assessment.

Based on the International Christianson Syndrome and NHE6 (SLC9A6) Gene Network Study, the current 91 study examined the largest sample to date of CS probands across the lifespan, importantly including 92 longitudinal follow-up data and a large proportion of adults. In total this study includes 44 probands, including 93 11 adults. This group of patients is more than three times as large as the largest prior report<sup>1</sup>, with a wider age 94 range of participants (age 2 to 32 years). Participants were enrolled as a result of a collaboration of 95 international participants, clinicians, researchers and the Christianson Syndrome Association (CSA). With a 96 focus on potential target symptoms for future clinical trials, the four primary aims of this study are to 1) define 97 new mutations and the range of NHE6 mutations in CS: 2) cross-sectionally and longitudinally examine the 98 99 clinical phenotype across the lifespan, as well as the adult phenotype and potential early mortality; and 3) longitudinally examine growth and maintenance of healthy weight of the probands across the lifespan. 100 Importantly, we present new mutations, including informative missense mutations, Also, through annual follow-101 up, we define a prominent component of the progressive phenotype in CS involving the longitudinal attenuation 102 of weight gain and growth, as well as loss of motor function with age. We have also observed deaths of 103 participants. In summary, given the size and the longitudinal design, the current study permits a quantitative 104 investigation of the CS phenotype across the lifespan, and importantly, the definition of the CS phenotype in 105 adulthood. 106

## 107 METHODS

Procedures: This Christianson Syndrome and NHE6 (*SLC9A6*) Gene Network Study was approved by the Institutional Review Board (IRB) at Lifespan Healthcare and Brown University. Informed consent was given by the parent/guardian of the participant. The procedures involved the initial enrollment and yearly follow-ups. We generated natural history data through both retrospective medical record review and history taking, as well as annual prospective follow-up assessments. At the time of this report, one-year, prospective follow-up data on 22 patients were available.

114

**Recruitment and Enrollment:** Enrollment criteria were adapted from Pescosolido et al.<sup>1</sup> and included males 115 at any age wherein: 1) there was a prior clinical genetic diagnosis involving mutation in the SLC9A6 gene; 2) 116 the participating child had an active clinician; and 3) the clinical phenotype was consistent with CS diagnostic 117 criteria. CS probands and their extended families were enrolled. Participants were recruited through close 118 collaboration with the family association, the Christianson Syndrome Association (CSA), participation in the 119 biannual international conferences for CS, and via genetic diagnostic labs. Participants were predominantly 120 enrolled remotely in this study due to our international recruitment that spans 11 countries. Materials were 121 translated into the native language of the family and remote assessments were conducted with a translator 122 when possible. DNA was isolated from blood or saliva samples. All NHE6 mutations were verified by Sanger 123 sequencing by sequencing all coding exons (1-16) and exon/intron junctions as previously described<sup>1</sup> except 124 where indicated in Table 1. 125

126

Clinical Assessment and Medical Record Review: Clinical data were collected by telephone, video-127 conferencing and/or in person assessments and through medical record collection. Standardized research 128 assessments were also filled out by parents/quardians. The Vineland Adaptive Behavior Scales-Second 129 Edition (VABS-2)<sup>16</sup> assessed adaptive functioning across the following domains: communication, social, daily 130 living, motor, and maladaptive behavior. Irritability and hyperactivity were assessed via the Aberrant Behavior 131 Checklist (ABC)<sup>17</sup>, a parent questionnaire to assess behavioral problems in individuals with developmental 132 disorders. A detailed medical and family history questionnaire, including items specific to CS, was administered 133 to parents/guardians. Height and weight were obtained from available medical notes. In-person standard 134

neurological examinations included assessments of cranial nerve, motor (e.g. muscle tone and reflexes),

136 coordination (e.g. gait), and sensory function that were performed by a board-certified neurologist (JSL).

137 Prospective follow-up involved an annual telephone or video interview to collect information regarding changes

- to medical, neurological, or behavioral symptoms experienced by the proband since the family's last contact
- 139 with the study. VABS-2 and ABC were administered, and new medical records were collected.
- 140

141	Statistical Analyses: The sample (n = 44) was divided into four groups, broadly based on developmental
142	stage at enrollment: toddlers (0-5 years; n = 11), children (6-11 years; n = 9), adolescents (12-16 years; n =
143	13), and adults (17-32 years; n = 11). ANOVA and chi-squared analysis were used to examine group
144	differences in clinical characteristics across developmental stages, inheritance/de novo, and mutation type. A
145	subset of the group (n = 22) completed the VABS-2 at baseline and re-assessment at the study 1-year follow-
146	up. VABS-2 subdomains were used to measure expressive language (Communication scale), interpersonal
147	skills (Social scale), fine motor skills (Motor scale), and gross motor skills (Motor scale) were examined. The
148	change in raw skills between baseline and follow-up was calculated to examine potential intra-individual
149	decline and analyzed using Pearson's correlation. Raw measurements of height/weight were converted to age
150	normed percentiles (WHO growth standards for 0-2 years <sup>18</sup> ; CDC growth curves for 2-20 years <sup>19</sup> ) and to z-
151	scores. To model physical stature across development, we used linear mixed model (with random slopes and
152	intercepts) for each variable of interest (i.e., height, weight) with the age of the child as the time basis. The
153	intercept and age at time point were modeled as fixed and random effects.

## 154 **RESULTS**

CS-associated Mutations: In total, 37 distinct families were enrolled with 44 affected males. Thirty-one unique 155 mutations were identified in the cohort (Table 1; Figure 1). Of the 31 unique mutations, there were: 15 156 frameshift and/or nonsense mutations: four deleterious missense mutations: nine splice mutations: two copy 157 number variant deletions; and one mutation that removes the first methionine residue. Of those with known 158 inheritance (29 of 37 families), 16 cases were inherited (55%) and 13 cases were de novo (45%). Notably, five 159 mutations were recurrent (i.e. occurred in more than one family). Each of the following mutations occurred in 160 two distinct families: c.899+1delGTAA (mutation 14). c.1024G>A (mutation 16). c.1148G>A (mutation 17). and 161 c.1710G>A (mutation 30). Mutation 25. c.1498C>T. was found in three families. These recurrent mutations 162 were inherited in three families not known to be related and were *de novo* in five families. Inheritance was 163 unknown in the three remaining families with recurrent mutations. No strong genotype-phenotype associations 164 were evident in the data (Supplemental Table 1). 165

166

167 **CS Core and Associated Symptoms Across the Lifespan:** In total, 44 males were evaluated with *SLC9A6* 168 mutations, ranging from age 2 to 32 years. In order to consider CS symptoms across developmental stages, 169 cross-sectional analysis was conducted across four age groups (Table 2): 0-5 years at enrollment (n = 11); 6-170 11 years (n = 9); 12-16 years (n = 13); and 17-32 years (n = 11). In terms of race and ethnicity: 11% of the 171 sample identified as Hispanic/Latino (n = 5); 89% identified as White (n = 39); 5% identified as Multi-racial (n = 172 2); 2% identified as Black (n = 1); and 2% identified as Other (n = 1). Participants were born in eleven different 173 countries and seven different primary languages were represented in these families.

Based on our prior study of 14 CS patients, we proposed CS core symptoms (present >85%) and 174 secondary symptoms (present in >35%).<sup>1</sup> Core symptoms included intellectual disability, non-verbal status. 175 epilepsy, ataxia, postnatal microcephaly, and hyperkinesis.<sup>1</sup> The previously proposed core symptoms were 176 upheld here in this larger study on average across age by combining all age groups (Table 2). Specifically, all 177 of the core symptoms were present in greater than 85%, including intellectual disability (100%), epilepsy 178 (100%), non-verbal/non-phrase speech (100%), microcephaly (95%), ataxia (95%), and hyperkinesia (93%). 179 Notably, we discerned that high pain tolerance represents a new core symptom when considering all age 180 groups together, present in over 85% (91%). 181

Secondary symptoms that occurred in 35-84% of participants included current sleep problems (51%). 182 unprovoked laughter (62%), visual acuity problems (52%), current GERD (56%), constipation (55%), eve 183 movement abnormalities (68%), regression (54%), swallowing problems (44%), and contractures (36%) (Table 184 2). Previously identified secondary symptoms such as prior Angelman syndrome diagnosis and Autism 185 Spectrum Disorder (ASD) diagnosis occurred in 29% and 18% of the current sample, respectively. ASD 186 diagnosis and prior Angelman diagnosis (approaching significance, p = .05) were more common in the older 187 groups, perhaps reflecting more access to accurate genetic testing in the younger group. Scoliosis occurred in 188 39% of participants: two participants had corrective surgeries for scoliosis between 15 to 20 years of age. 189 While the core symptoms were relatively stable across age groups, there were several notable exceptions. 190 Absence of phrase speech, intellectual disability, ataxia and epilepsy were stable across all age groups. We 191 found 80% of the youngest age group (below our cut-off for core symptoms) had microcephaly which elevated 192 to 100% in all older age groups, reflecting that idea that the microcephaly in CS has a strong postnatal 193 component (Table 3). This variation in head circumference data reflecting decreases across ages approached 194 significance (p = .089). Similarly, 73% of participants had a high pain threshold in the youngest age group (0-5 195 years old) which elevated to above 85% (our cut-off for core symptoms) in the older age groups; therefore, 196 197 although prevalent in the voungest age group, high pain threshold should not be considered a strict core symptom in the youngest age group (Table 3). In the current group, ataxia was present in 82% of participants 198 in the youngest age group, and in 100% of subsequent age groups, again suggesting that ataxia worsens with 199 age. In line with these observations, with regard to the ability to walk, 100% of participants report walking 200 unaided by or before age 5; however, ability to walk unaided is lost in approximately 20% of participants in the 201 6 to 16 groups and 30% are reported as not able to walk unaided in the oldest group (17+ years old). Finally, 202 with regard to hyperkinesis, this core symptom was present in 100% of the participants in the two younger age 203 groups, and 92% and 82% of the oldest age group, indicating that hyperkinesis does not meet the cut-off for a 204 core-symptom in the oldest age group. Concurrent with these data, we observe that the hyperactivity subscale 205 scores on the Aberrant Behavior Checklist (ABC) are most severe in the younger groups and less prominent in 206 the oldest group (Table 2), although this does not reach statistical significance. 207

There were statistically significant differences across developmental groups for some reported symptoms or phenotypic features that are particularly notable. There were significant group differences in the rate of current

constipation, prior history of regression, adaptive function (including social, communication, and daily living 210 subscores) and number of hospitalizations (p < .05): each of these experiences were most common in the 211 adult group (Table 2). Importantly, 100% of participants in the oldest age group reported notable problems with 212 constipation (p = .002). With regard to regression, reports of any regression at some point in their lifetime 213 increased significantly with age from toddlers (30%), children (44%), adolescents (50%), and adults (90%) (p = 214 215 .047). With regard to adaptive functioning, age-normed Vineland scores appeared stable in toddlers and children, and then dropped in the adolescent group and again in the adult group (p < .001 for communication, p 216 < .001 social and daily living, and p < .0005 for adaptive functioning). While not representing a statistically 217 significant difference across groups (p = .305), it is notable that the highest level of inability to walk is 218

experienced in the adult group at approximately 30% (Table 2).

220

Longitudinal Assessment of Growth and Physical Stature across the Lifespan in CS: Adult patients with 221 CS have been described as having a thin body habitus<sup>3</sup>: however, systematic analysis of growth in CS across 222 the lifespan has not been conducted. To study growth in CS across the lifespan, raw measurements of height 223 and weight were converted to age-normed percentiles (WHO growth standards for 0-2 years<sup>18</sup>; CDC growth 224 curves for 2-20 years<sup>19</sup>) and to z-scores. To model physical stature across development, we used linear mixed 225 model (with random slopes and intercepts) for each variable of interest (i.e., height, weight) with the age of the 226 child as the time basis. The intercept and age at time point were modeled as fixed and random effects. The 227 height (n = 24) and weight (n = 30) obtained at clinical appointments was analyzed via mixed linear modeling 228 of age-based percentiles (Figure 2). While height and weight naturally increased with time (Figure 2A and 2B), 229 the age-normalized weight, i.e. the z-score (n = 30; total data points = 116; range = 1-12 points per person) 230 linearly declined over time (slope p < .001) (Figure 2C). Height z-score (n = 24; total data points = 81; range = 231 1-11 points per person) also linearly declined over time (slope p < .001). Of note, the predicted intercept for the 232 model at birth were within normal ranges; however, as shown the model demonstrates a progressive decline in 233 growth in CS relative to normal growth with age (Figure 2). Of relevance to challenges in growth and nutrition, 234 approximately 30% (13/44) participants had G-tubes placed. Approximately 38%, 23%, 23% and 15% had their 235 G-tubes placed during ages of 0-5, 6-11, 12-16, or 17+ years of age. Indications for G-tube placement have 236

- been failure to thrive (FTT), most often at the younger ages, and inability to eat across all ages, generally
- related to challenges with swallowing.
- 239

Adaptive, Behavioral, and Motor Functioning across the Lifespan: Cross-Sectional Findings, Parent-240 reported adaptive and behavioral data were also available for a subsample of the males (n = 27-31). When 241 examining differences across the cohort by current developmental stage (cross-sectional analysis), a 242 statistically significant difference across groups was identified (p < .0005) in age-normed overall adaptive 243 244 functioning. Specifically, older participants had lower age-normed abilities than younger participants, in that the vounger participants had abilities more similar to their same-aged peers while the abilities of the older 245 participants were further below those of their same-aged peers (Table 2). In further examining across these 246 cross-sectional age groups, there were no significant differences between age groups in hyperactivity or 247 irritability at baseline (Table 2; ABC). 248 249 Longitudinal Adaptive/Motor Findings. Importantly, we also conducted a longitudinal follow-up analysis through 250 investigation of change in adaptive function in individuals (n = 22), at baseline and at a 1-year follow-up time 251 252 point. The change in skills between baseline and follow-up was correlated to age at enrollment. Results showed that participant age was negatively correlated with change in fine motor skills (r = -.50; p = .028) and 253

gross motor skills (r = -.63; p = .002; Figure 3). Specifically, 5 of 6 adults (83%) experienced a loss in multiple fine motor skills such as picks up small objects with thumb and fingers and moves object from one hand to the other. Expressive language and interpersonal skills change were not significantly correlated with age (Figure 3). These longitudinal studies suggest that older participants are at risk for losing previously acquired skills, particularly in the motor domain, which is observable by parents/guardians at a one-year follow-up. Therefore, these longitudinal studies augment the above cross-sectional studies.

260

Neurological Exam. Standardized, in-person motor examination was performed by a board-certified neurologist
 (JSL). Twelve patients were directly examined (Supplemental Table 2). The direct assessment of patients
 additionally supports the interpretation that there is age-related worsening of motor function. Older patients (i.e.
 age 20 and greater), present with evidence of motor dysfunction with signs of corticospinal tract, i.e. upper

- 265 motor neuron damage, such as increased tone, weakness, increased and abnormal reflexes. These older
- subjects also have evidence of cerebellar dysfunction including tremor and truncal ataxia, as evidenced by
- 267 wide based gait. Thus, the clinical phenotype includes upper-motor neuron involvement that emerges
- particularly in adulthood, as well as cerebellar dysfunction that is also progressive but presents first in early
   adulthood.
- 270
- 271 **Participant Deaths**: Three of the 44 participants in this described cohort died (6.8%) during the duration of the
- study. One participant, who also may have had other contributing genetic mutations, died between 6 to 10
- 273 years of age due to complications caused by a worsening neurological state and increased seizure frequency.
- 274 The adult participants died between the ages of 20 to 25 and 30 to 35 years in their homes due to conditions
- related to infirmity, such as pneumonia.

#### 276 **DISCUSSION**

This study represents the largest to date of patients with Christianson Syndrome (CS) with confirmed NHE6 277 mutations. This also is the first study to date as part of the International Christianson Syndrome and NHE6 278 (SLC9A6) Gene Network Study, presenting longitudinal follow-up and systematic study of CS into adulthood. 279 Forty-four individuals with 31 unique NHE6 mutations, age 2 to 32 years, were followed prospectively, herein 280 reporting baseline, 1-year follow-up, and retrospective natural history. Among the most prominent results are: 281 first, the large range of mutations, wherein there are some notable new missense mutations (discussed below); 282 second, we have also defined the core symptoms of CS and the dynamics of these symptoms across the 283 lifespan, and also, added a novel and important new core symptom, namely the high pain threshold that 284 children exhibit, particularly after age 6; third, we present longitudinal follow-up data demonstrating that CS 285 patients do show decreases in motor function with age; fourth, we present data exhibiting the challenges in 286 maintenance of a healthy weight and reductions of body-mass index with age; and finally, fifth, in this study 287 through longitudinal follow-up, we were able to provide important information with regard to CS features in 288 adulthood and we begin to address the question of life expectancy and mortality. This international CS study 289 has thereby defined future treatment targets, and also provides natural history data of the sort that will support 290 291 future clinical trials.

292

## 293 Genetic Diversity in CS and Genotype-Phenotype Relationships

We present 31 unique mutations in 44 affected males with CS. The vast majority are clear complete or near 294 complete loss-of-function mutations, with more than 80% as frameshift/nonsense, splice (29% of total) or 295 highly deleterious copy number variant deletions. A minority represent missense mutations which are likely 296 loss-of-function. There is a possibility that these missense mutations may represent incomplete loss-of-function 297 298 mutations; however, at present the evidence to support this is only anecdotal. In the current dataset, there is no statistical evidence of genotype-phenotype correlations, providing further support that the majority of NHE6 299 mutations are complete or near complete loss-of-function. Prior studies in patient-derived induced pluripotent 300 stem cells have demonstrated that nonsense mutations are subject to nonsense mediated mRNA decay.<sup>14</sup> Of 301 note, the G383D mutation which has been studied functionally in iPSCs exhibits some residual proteins.<sup>14</sup> 302 Another notable finding, in terms of genetic mutations, is that we present here a patient with the L582P 303

- mutation which represents a rare missense mutation in the cytoplasmic tail of NHE6 that is associated with the
   CS phenotype. The proband with this L582P mutation exhibits core CS symptoms including intellectual
- disability, non-verbal, and microcephaly.
- 307

# 308 Natural History of Primary and Secondary CS Symptoms with Age

Previously established core diagnostic features of CS<sup>1</sup> were confirmed in this sample of probands, including 309 intellectual disability (100%), epilepsy (100%), non-verbal/non-phrase speech (100%), postnatal microcephaly 310 (95%), ataxia (95%), and hyperkinesia (93%). High pain tolerance, not previously identified as a core feature of 311 CS, was present in 91% of probands, and therefore, we support the inclusion of high pain tolerance as a new 312 core diagnostic feature. Importantly, clinicians and caregivers should be aware of this symptom, in order to 313 understand how people with CS may respond to injury. Minimal response to pain may not be a good indicator 314 in the evaluation of the seriousness of an injury. Overall, with regard to core symptoms of CS, we show here 315 that there is some evolution of these symptoms with age, such that microcephaly, ataxia and high pain 316 threshold are not present in over 85% of CS patients until age 6. Notably, this provides further support that the 317 microcephaly in CS is indeed postnatal microcephaly, and generally not primary microcephaly. Furthermore, 318 hyperkinesia appears to dissipate with age, which may be mediated by age-related worsening of motor 319 320 function.

Secondary symptoms of CS<sup>1</sup> were also highly represented in the sample, including GERD (56%), eve 321 movement abnormalities (68%), prior regression (54%), and prior diagnosis of Angelman syndrome (29%) and 322 autism (18%). The majority of these symptoms were similarly observed across developmental periods. 323 However, we suspect a prior diagnosis of Angelman syndrome will become less common in younger CS males 324 in the future due to the availability and advances in genetic testing. Indeed, no toddlers were previously 325 diagnosed with Angelman syndrome. Additional symptoms such as current sleep problems (51%), visual acuity 326 problems (52%), and swallowing problems (44%) were relatively stable across developmental periods. 327 Importantly, the adult cohort experienced a higher rate of select medical complications, particularly 328 gastrointestinal symptoms, such as gastroesophageal reflux, and constipation. Adult CS patients had 329 significantly greater hospitalizations, along with more frequent infections. Unprovoked laughter becomes more 330 prominent in adolescence/adulthood, whereas in Angelman syndrome laughter appears to decrease with 331

age.<sup>20-22</sup> Also, importantly, scoliosis occurred in greater than a third of patients which worsens with age,

requiring surgery in a subset.

334

# 335 Challenges in Maintaining a Healthy Weight During Growth and Aging in CS

Clinical records were analyzed to examine height and weight growth across development as they represent 336 secondary CS symptoms.<sup>1</sup> While probands continued to make raw score gains in pounds and inches across 337 time, their slowed rate of growth resulted in a similar pattern of decreasing age-normed score across 338 development for height and weight. Mixed model results estimated height and weight to be in the average or 339 typically developing range at birth. However, height fell to below one standard deviation (SD) below the mean 340 by 7 years and two SDs by 19 years old. Weight fell to below one SD by 8 years old and two SDs by 15 years 341 old. While there was little evidence of loss in body mass in our data, models were only calculated from 0-20 342 vears (based on available developmental normative data). These analyses of body size highlight abnormalities 343 in growth in CS: however, these data call for important future studies. Healthy weight should become a target 344 symptom in growth and adulthood. Studies of nutrition and healthy weight in adulthood are warranted, and 345 consideration of the caloric and nutritional requirements of men with CS will need to become a critical subject 346 347 in future studies.

348

# 349 Longitudinal Data in CS Demonstrate Progression of Motor Symptoms

We present natural history data reflecting both retrospective methods, as well as prospective study at 1-350 year follow-up and cross-sectional information on families. The majority of probands (54%) had a history of 351 parent-reported developmental regression that increased in prevalence across development, with 30% of 352 toddlers, 44% of children, 50% of adolescents, and 90% of adults experiencing prior regression. This was not 353 specific to any of the subdomains, although 60% of adults had a prior motor regression and 45% of adults had 354 a prior speech regression. This is consistent with our prior study of regression in 50% of CS probands, most 355 notably in speech and motor domains.<sup>1</sup> Additionally, loss of social skills was noted in about one-third of 356 children with regressions. 357

To complement these and prior cross-sectional and retrospective analyses, we examined changes in language, social, and motor functions over a 1-year interval follow-up. Here, we find that there was a negative

association between participant age at enrollment and fine/gross motor function loss, in that adults
experienced a notable loss of motor functions in this 1-year interval. These data identify motor function as a
target symptom for treatment and prevention of decline. These prospective follow-up data are particularly
notable as we are able to observe a measurable decline in this relatively short time-line of 1-year. This finding
is particularly valuable and hopeful as clinical trials that may target the progression of these motor symptoms
will benefit from observations of this strong effect size in time-frames that appear feasible for a robust trial.

366

## 367 Limitations of this study

While this is the largest study to date on CS, the sample size (n = 44) is modest, and definition of more rare 368 events in CS will require a larger and more highly-powered sample. Additionally, while this study does include 369 prospective, intra-individual longitudinal data, many findings still rely on natural history data from retrospective 370 clinical records or a convenience sample. For example, this study relies on a clinical diagnosis of autism, as 371 opposed to prospectively measuring autism symptoms using standardized assessments such as the Autism 372 Diagnostic Observation Schedule (ADOS)<sup>23</sup>, Autism Diagnostic Interview-Revised (ADI-R)<sup>24</sup>, and Social 373 Communication Questionnaire (SCQ)<sup>25</sup>. Fewer CS patients were clinically diagnosed with autism (18%, 7 out 374 of 40) compared to our prior study (43%, 6 out of 14).<sup>1</sup> While there is a strong agreement between a clinical 375 diagnosis and these measurements<sup>26-28</sup>, we may be underestimating autism-related features in CS. Indeed. in 376 our prior study using standardized assessments in a small subset of CS patients, we found a majority met 377 diagnostic criteria for autism by the ADI-R (100%, 3 out of 3) and SCQ (89%, 8 out of 9).<sup>1</sup> In addition, this study 378 does not examine the clinical progression of epilepsy symptoms, treatment and outcome. Our prior study had a 379 detailed cross-sectional analysis<sup>1</sup>, and an in-depth analysis of epilepsy natural history is beyond the scope of 380 the current manuscript and is being addressed in a parallel study. Of note, Dr. Arnold Christianson in his 381 original study in a large South African pedigree suggested that there may be a risk of premature mortality in 382 CS. In the course of our study, we have observed the death of three total participants. While this may appear 383 as an elevated risk given this profound neurologic condition, our sample size remains too small to discern the 384 specific underlying susceptibilities that may put males with CS at an increased mortality risk in childhood or in 385 aging. Again, it currently remains unclear whether premature mortality is a risk factor in CS. 386

## 388 Summary

389	As a part of the International Christianson Syndrome and NHE6 (SLC9A6) Gene Network study, in
390	collaboration with the Christianson Syndrome Association, we present the largest study to date of male
391	patients with CS. Overall, this study has identified a large range of loss-of-function mutations, including several
392	novel missense variants. This study is notable for the identification of a new core symptom (high pain
393	threshold) and the natural progression into adulthood. This study has the largest group of adults with CS, and
394	we have defined the clinical progression of motor symptoms. In addition, we identify a decline in body-mass
395	index with age as an important treatment target moving forward. In conclusion, this study identifies several
396	target symptoms - particularly health weight gain and motor symptoms that progress with a natural history
397	that may make them amenable to intervention in a future clinical trial. As this CS study grows, the findings
398	presented here, and in future studies, will enhance clinical readiness as targeted treatments become available.

- 399 Acknowledgements: The authors would like to thank the families for participating in this study. We would also
- 400 like to thank the Christianson Syndrome Association for their help with this study. This work was supported by
- 401 National Institutes of Health Grants R01NS113141, R01MH102418, R01MH105442, and R21MH115392 to
- 402 E.M.M. EMM had full access to all of the data in the study and takes responsibility for the integrity of the data
- and the accuracy of the data analysis. None of the authors have a financial conflict of interest.

## 404 FIGURE LEGENDS

- 405 **Figure 1. Christianson syndrome-associated NHE6 mutations.**
- 406 A total of 31 unique NHE6 mutations were identified in 44 CS male probands across 37 families. Pathogenic
- 407 NHE6 mutations include: frameshift and/or nonsense (n = 15, cyan or orange), deleterious missense (n = 4,
- 408 black), splice (n = 9), CNVs (n = 2, green) and one that removes the first methionine residue. Out of CS
- 409 pedigrees with known inheritance (78%, 29 out of 37 families), 55% were inherited (16 out of 29 pedigrees)
- 410 and 45% were *de novo* (13 out of 29 pedigrees). A total of five mutations were recurrent across multiple
- 411 pedigrees: c.899+1delGTAA (mutation 14, 2 pedigrees), c.1024G>A (mutation 16, 2 pedigrees), c.1148G>A
- 412 (mutation 17, 2 pedigrees), c.1498C>T (mutation 25, 3 pedigrees) and c.1710G>A (mutation 30, 2 pedigrees).
- 413 The following mRNA isoforms are used: NM\_001042537, NM\_006359, NM\_001379110.1 and
- 414 NM\_001177651. TM=transmembrane.
- 415

# 416 Figure 2. Changes in height and weight across development.

- 417 (A) Raw score of height (inches) by age (years) from 24 CS probands spanning <1-19 years. Height increases
- 418 over time (Pearson's correlation,  $R^2=0.92$ ).
- (B) Raw score of weight (pounds) by age (years) from 30 CS probands spanning <1-19 years. Weight
- 420 increases over time (Pearson's correlation, R<sup>2</sup>=0.90).

(C) Estimated age-normed height and weight based on liner mixed model analysis. Both height (slope 421 p<0.001) and weight (slope p<0.001) significantly decline over time. Raw height (n = 24, total data points = 81) 422 and weight (n = 30, total data points = 116) measurements were converted to age-normed percentiles (WHO 423 growth standards for 0-2 years<sup>18</sup>; CDC growth curves for 2-20 years<sup>19</sup>) and z-scores. Our linear mixed model 424 (random slopes and intercepts) of age-based percentiles for height and weight modeled the intercept and age 425 at time point as fixed and random effects, respectively. Covariance parameters for height were large relative to 426 their standard errors with statistically significant intercept (slope p=0.003), slope (p=0.016) and covariance of 427 intercept and slope (p=0.046). Covariance parameters for weight were large relative to their standard errors 428 with statistically significant intercept (slope p=0.002), slope (p=0.016) and covariance of intercept and slope 429 (p=0.023). 430

- 432 Figure 3. Longitudinal changes in motor, language, and social functioning over 1-year period.
- Parent-rated changes in gross motor (A), fine motor (B), expressive language (C), and interpersonal/social
- 434 functioning (**D**) from enrollment to 1-year follow-up (n = 22). Each point represents an individual proband. Raw
- 435 score change between enrollment and 1-year follow-up is plotted by age at enrollment. Changes in gross (A,
- 436 R<sup>2</sup>=0.40, p=0.002) and fine (**B**, R<sup>2</sup>=0.25, p=0.028) motor is significantly correlated with age, as older age is
- 437 associated with greater loss of motor skills over a 1-year period. There is no association between age and
- 438 changes in expressive language (**C**, R<sup>2</sup>=0.002, p=0.83) or social functioning (**D**, R<sup>2</sup>=0.00, p=0.96) over this
- 439 timespan. Pearson's correlation.

# 440 **TABLE LEGENDS**

- Table 1. NHE6 mutations found in 44 affected males across 37 families.
- All transcript positions are based on NM\_001042537.1 and protein sequences are based on NP\_001036002.1.
- 443 Coordinates reported are hg19. For mutations found in more than one individual, the number of individuals is
- 444 denoted in brackets under Variant Type. For mutations found in more than one family, the number of families is
- 445 denoted in brackets under Inheritance.
- <sup>446</sup> <sup>a</sup> Indicates mutations not confirmed by Sanger sequencing and data based solely on medical records.
- 447

# Table 2. Clinical characteristics of CS males across developmental cohorts.

- + Denotes numbers approaching statistical significance (p < .05). Italicized domains represent proposed core
- 450 CS symptoms. Adaptive functioning score from VABS-2 is a composite of the communication, daily living skills,
- 451 socialization and motor skills domain scores. GERD=Gastroesophageal reflux disease. ABC=Aberrant
- 452 Behavior Checklist. VABS-2=Vineland Adaptive Behavior Scales-2<sup>nd</sup> Edition.
- 453

# 454 **Table 3. Core symptoms of Christianson syndrome by age group.**

- List of core symptoms found in >85% of CS males across the following age groups: toddler (2.5-5 years),
- 456 childhood (6-11 years), adolescence (12-16 years) and adulthood (17-32 years).

# 457 SUPPLEMENTARY MATERIALS

- 458 **Supplementary Table 1. Clinical characteristics of CS males by inheritance and mutation type.**
- Adaptive functioning score from VABS-2 is a composite of the communication, daily living skills, socialization
- 460 and motor skills domain scores. GERD=Gastroesophageal reflux disease. ABC=Aberrant Behavior Checklist.
- 461 VABS-2=Vineland Adaptive Behavior Scales-2<sup>nd</sup> Edition.
- 462
- 463 **Supplementary Table 2. Neurological examination of CS probands.**
- 464 Neurological examination of 12 CS males. L=Left. R=Right. L>R=Left greater than right. R>L=Right greater
- than left. s.p.=Status post.

## **REFERENCES**

407		
468	1. Pescosolido MF, Stein DM, Schmidt M, et al. Genetic and phenotypic diversity of NHE6 mutations in	
469	Christianson syndrome. Annals of neurology. Oct 2014;76(4):581-93. doi:10.1002/ana.24225	
470	2. Gilfillan GD, Selmer KK, Roxrud I, et al. SLC9A6 mutations cause X-linked mental retardation,	
471	microcephaly, epilepsy, and ataxia, a phenotype mimicking Angelman syndrome. The American Journal of	
472	Human Genetics. 2008;82(4):1003-1010.	
473	3. Christianson AL, Stevenson RE, van der Meyden CH, et al. X linked severe mental retardation,	
474	craniofacial dysmorphology, epilepsy, ophthalmoplegia, and cerebellar atrophy in a large South African kindre	эd
475	is localised to Xq24-q27. J Med Genet. Oct 1999;36(10):759-66. doi:10.1136/jmg.36.10.759	
476	4. Schroer RJ, Holden KR, Tarpey PS, et al. Natural history of Christianson syndrome. Am J Med Gener	L
477	<i>A</i> . Nov 2010;152a(11):2775-83. doi:10.1002/ajmg.a.33093	
478	5. Tarpey PS, Smith R, Pleasance E, et al. A systematic, large-scale resequencing screen of X-	
479	chromosome coding exons in mental retardation. Nature genetics. May 2009;41(5):535-43. doi:10.1038/ng.30	37
480	6. Ouyang Q, Lizarraga SB, Schmidt M, et al. Christianson syndrome protein NHE6 modulates TrkB	
481	endosomal signaling required for neuronal circuit development. Neuron. 2013;80(1):97-112.	
482	7. Pescosolido MF, Ouyang Q, Liu JS, Morrow EM. Loss of Christianson Syndrome Na+/H+ Exchanger	6
483	(NHE6) Causes Abnormal Endosome Maturation and Trafficking Underlying Lysosome Dysfunction in	
484	Neurons. <i>Journal of Neuroscience</i> . 2021;	
485	8. Lee Y, Miller MR, Fernandez MA, et al. Early lysosome defects precede neurodegeneration with	
486	amyloid-β and tau aggregation in NHE6-null rat brain. <i>Brain</i> . 2021;	
487	9. Stromme P, Dobrenis K, Sillitoe RV, et al. X-linked Angelman-like syndrome caused by Slc9a6	
488	knockout in mice exhibits evidence of endosomal-lysosomal dysfunction. Brain : a journal of neurology. Nov	
489	2011;134(Pt 11):3369-83. doi:10.1093/brain/awr250	

- 490 10. Xu M, Ouyang Q, Gong J, et al. Mixed Neurodevelopmental and Neurodegenerative Pathology in
- 491 Nhe6-Null Mouse Model of Christianson Syndrome. eNeuro. Nov-Dec 2017;4(6)doi:10.1523/eneuro.0388-
- 492 17.2017
- 493 11. Fernandez MA, Bah F, Ma L, et al. Loss of endosomal exchanger NHE6 leads to pathological changes
- 494 in tau in human neurons. Stem Cell Reports. Sep 13 2022;17(9):2111-2126. doi:10.1016/j.stemcr.2022.08.001
- 495 12. Garbern JY, Neumann M, Trojanowski JQ, et al. A mutation affecting the sodium/proton exchanger,
- 496 SLC9A6, causes mental retardation with tau deposition. *Brain*. 2010;133(5):1391-1402.
- 497 13. Bosemani T, Zanni G, Hartman AL, et al. Christianson syndrome: spectrum of neuroimaging findings.
- 498 Neuropediatrics. Aug 2014;45(4):247-51. doi:10.1055/s-0033-1363091
- 499 14. Lizarraga SB, Ma L, Maguire AM, et al. Human neurons from Christianson syndrome iPSCs reveal
- 500 mutation-specific responses to rescue strategies. *Science translational medicine*. Feb 10
- 501 2021;13(580)doi:10.1126/scitranslmed.aaw0682
- Ilie A, Gao AYL, Boucher A, *et al.* A potential gain-of-function variant of SLC9A6 leads to endosomal
  alkalinization and neuronal atrophy associated with Christianson Syndrome. *Neurobiol Dis.* Jan 2019;121:187doi:10.1016/j.nbd.2018.10.002
- 505 16. Sparrow S, Balla, D., Cicchetti, D. *Vineland Adaptive Behavior Scales*. American Guidance Service;
  506 2005.
- Achenbach TM, Rescorla, L. A. *Manual for the ASEBA school-age forms & profiles: An integrated system of multi-informant assessment*. University of Vermont, Research Center for Children, Youth, &
  Families; 2001.
- 18. Organization WH. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-forLength, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. World Health
  Organization; 2006.

- 19. Kuczmarski RJ, Ogden, C., Grummer-Strawn, L., Flegal, K. M. CDC Growth Charts: United States.
- 514 Advance Data Report No. 314. National Center for Health Statistics; 2000.
- 515 20. Buntinx IM, Hennekam RC, Brouwer OF, et al. Clinical profile of Angelman syndrome at different ages.
- 516 American journal of medical genetics. Mar 27 1995;56(2):176-83. doi:10.1002/ajmg.1320560213
- 517 21. Laan LA, den Boer AT, Hennekam RC, Renier WO, Brouwer OF. Angelman syndrome in adulthood.
- 518 American journal of medical genetics. Dec 18 1996;66(3):356-60. doi:10.1002/(sici)1096-
- 519 8628(19961218)66:3<356::Aid-ajmg21>3.0.Co;2-k
- 520 22. Adams D, Horsler K, Mount R, Oliver C. Brief Report: A Longitudinal Study of Excessive Smiling and
- 521 Laughing in Children with Angelman Syndrome. Journal of autism and developmental disorders. Aug
- 522 2015;45(8):2624-7. doi:10.1007/s10803-015-2404-y
- Lord C, Risi S, Lambrecht L, *et al.* The autism diagnostic observation schedule-generic: a standard
   measure of social and communication deficits associated with the spectrum of autism. *Journal of autism and developmental disorders.* Jun 2000;30(3):205-23.
- 526 24. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview—Revised: A revised version of a
- diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *Journal of autism and developmental disorders*. 1994;24(5):659-685. doi:10.1007/BF02172145
- 529 25. Rutter M, Bailey A, Lord C. Social communication questionnaire. Los Angeles, CA: Western
  530 Psychological Services; 2003.
- Le Couteur A, Haden G, Hammal D, McConachie H. Diagnosing autism spectrum disorders in preschool children using two standardised assessment instruments: the ADI-R and the ADOS. *Journal of autism and developmental disorders*. Feb 2008;38(2):362-72. doi:10.1007/s10803-007-0403-3
- 534 27. Kim SH, Lord C. Combining information from multiple sources for the diagnosis of autism spectrum 535 disorders for toddlers and young preschoolers from 12 to 47 months of age. *Journal of child psychology and* 536 *psychiatry, and allied disciplines*. Feb 2012;53(2):143-51. doi:10.1111/j.1469-7610.2011.02458.x

- 537 28. Lebersfeld JB, Swanson M, Clesi CD, O'Kelley SE. Systematic Review and Meta-Analysis of the
- 538 Clinical Utility of the ADOS-2 and the ADI-R in Diagnosing Autism Spectrum Disorders in Children. Journal of
- 539 autism and developmental disorders. Nov 2021;51(11):4101-4114. doi:10.1007/s10803-020-04839-z

#### **FIGURE 1.**









## 545 FIGURE 3.



lutation	cDNA Position	Protein Position	Exon/Intron	Variant Type	Inheritance	Genomic Coordinates
I	2073bp deletion including exon 1 and some of intron 1	-	Exon I/IntronI	Deletion (2)	Unknown	chrX:135066366 135068439
2	c.1A>G	p.MI?	Exon I	Start Lost	Inherited	chrX:135067662
3	c.205C>T	p.Q69*	Exon I	Nonsense (2)	Inherited	chrX:135067866
4	c.335_336delTG	p.VII2Gfs*I3	Exon 2	Frameshift (2)	Inherited	chrX:135076954 135076955
5	c.526-1G>A	-	Intron 2	Splice	De novo	chrX:135080266
6	c.540_547dup	p.F183fs*1	Exon 3	Frameshift	Unknown	chrX:135080281 135080288
<b>7</b> ª	c.603+1G>A	-	Intron 3	Splice	Inherited	chrX:135080345
8	c.604-1G>T	-	Intron 3	Splice	Inherited	chrX:135080640
9	c.604-1G>A	-	Intron 3	Splice (2)	Inherited	chrX:135080640
10	c.630_631insT	p.1211Yfs*53	Exon 4	Frameshift (3)	Inherited	chrX:135080668
П	c.680+1G>A	-	Intron 4	Splice	De novo	chrX:135080718
12	c.680+5G>A	-	Intron 4	Splice	De novo	chrX:135080722
13	c.899+1G>A	-	Intron 6	Splice	Inherited	chrX:13508437
14	c.899+IdelGTAA	-	Intron 6	Splice (2)	Unknown (I) Inherited (I)	chrX:135084373 135084376
15	c.953_954delCA	p.T318Sfs*59	Exon 7	Frameshift	Inherited	chrX:135092654 135092655
16	c.1024G>A	p.G342R	Exon 7	Missense (2)	De novo (2)	chrX:13509272
17	c.1148G>A	p.G383D	Exon 9	Missense (2)	De novo (2)	chrX:13509550
18	c.1222_1226delCATAG	p.H408Nfs*2	Exon 9	Frameshift	De novo	chrx:135095582 135095586
19	120.7kb deletion from intron 10 through 3'-untranslated region	-	Intron 10 to Exon 16	Deletion	Inherited	chrX:135098247 135218928
20	c.1380_1389delinsGTCTTGGGAAGAC T	p.N460Kfs*12	Exon 11	Frameshift	Inherited	chrX:135104774 135104780
<b>2</b> 1ª	c.1402_1405del	p.L468lfs*15	ExonII	Frameshift	Unknown	chrx:135104796 135104799
22	c.1414insA	p.R472Kfs*4	Exon 11	Frameshift	De novo	chrX:13510480
23	c.1462+1G>C	-	Intron 11	Splice	Unknown	chrX:13510485
24	c.1472G>A	p.G491D	Exon 12	Missense	Inherited	chrX:13510649
25	c.1498C>T	p.R500*	Exon 12	Nonsense (3)	Inherited (2) Unknown (1)	chrX:13510652
26	c.1568G>A	p.W523*	Exon 12	Nonsense	De novo	chrX:13510659
27	c.1569G>A	p.W523*	Exon 12	Nonsense	Unknown	chrX:13510659
<b>28</b> ª	c.1631C>G	p.S544*	Exon13	Nonsense	De novo	chrX:13511230
29	c.1639G>T	p.E547*	Exon 13	Nonsense (2)	Inherited	chrX:13511231
30	c.1710G>A	p.W570*	Exon 14	Nonsense (2)	De novo (I) Unknown (I)	chrX:13511563
31	c.1745T>C	p.L582P	Exon 15	Missense (1)	De novo	chrX:13512225

#### 547

Note. All transcript positions are based on NM\_001042537.1 and protein sequences are based on NP\_001036002.1. Coordinates reported are hg19. Under Variant

Type, if the mutation is found in more than one individual, the total number of individuals are indicated in brackets. Under Inheritance, if the mutation is found in more than one family, the number of families are indicated in brackets. <sup>a</sup> Indicates mutations wherein confirmation by Sanger sequencing was not performed, and the

data are based on the medical record alone.

#### 552 Table 2. Clinical Characteristics of CS Males across Developmental Cohorts

					Adolescents			
	n	Total sample	Toddlers	Children	(12-16 yrs; n	Adults		
		(n =44)	(2.5-5 yrs; n = 11)	(6-11 yrs; n = 9)	(= 13)	(17-32 yrs; n = 11)	F/X <sup>2</sup>	p
General		· · · ·			,			•
Age at Enrollment	44	12.2 (7.1)	4.4 (1.3)	7.5 (1.5)	14 (1.6)	21 (4.1)	106	<.001
Age at CS Diagnosis, m (sd)	44	8.0 (6.6)	3.4 (1.5)	4.0 (2.2)	7.4 (3.6)	16.5 (7.0)	22.3	<.001
Able to Walk Currently (%)	41	34 (83)	(100)	7 (78)	9 (82)	7 (70)	3.6	305
Phrase Speech	46	0%	0%	0%	0%	0%	-	-
		•/•	0,0	0,0	0,0	0,0		
Neurological, n (%)								
Intellectual Disability	42	42 (100)	11 (100)	9 (100)	12 (100)	10 (100)	-	-
Ebilebsy	42	42 (100)	11 (100)	9 (100)	12 (100)	10 (100)	-	-
Microcephaly	41	39 (95)	8 (80)	9 (100)	12 (100)	10 (100)	6.5	.089
Ataxia	39	37 (95)	9 (82)	8 (100)		9 (100)	5.4	.147
Autism Spectrum Disorder	40	7 (18)	( <u>0</u> )	2 (29)	3 (25)		2.0	574
Hyperkinesia	43	40 (93)	11(100)	9 (100)	11 (92)	9 (82)	37	300
Prior Angelman Dx	42	12 (29)	0 (0)	4 (44)	3 (25)	5 (50)	7.8	050+
High Pain Tolerance	43	39 (91)	8 (73)	9 (100)	12(100)	10 (91)	637	095
Lipprovokod Laughtor	40	26 (62)	5 (45)	A (AA)	9 (75)	8 (80)	4 69	.075
	72	20 (02)	2 (20)	(דד) ד (22) ב	7 (75) A (26)	6 (60) E (E4)	70, 74	.176
Viewel A guitty Problems	40	17 (30)	2 (20)	5 (55) 4 (44)	4 (50)	5 (56)	2.0	.151
	42	22 (52)	7 (04)	4 (44)	6 (50)	3 (30)	.04	.041
Eye Movement	38	26 (68)	6 (60)	7 (78)	10 (83)	3 (43)	4.1	.257
Abnormalities								
Medical Status, n (%)	40	10 (44)	F (4F)	2 (22)	F (42)	7 (( 1)	25	222
	43	17 (44)	5 (45)	2 (22)	5 (42)	7 (64)	3.5	.323
GERD	41	23 (56)	7 (64)	2 (22)	7 (58)	7 (78)	6.2	.103
Current Constipation	40	22 (55)	6 (55)	3 (33)	2 (22)	11 (100)	14.6	.002
Osteopenia	39	2 (5)	0 (0)	0 (0)	1 (10)	1 (10)	2.0	.572
Current Sleep Problems	43	22 (51)	7 (64)	5 (56)	5 (42)	5 (45)	1.3	./22
Frequent Infections	41	9 (22)	2 (18)	2 (22)	0 (0)	5 (50)	7.78	.051+
# of Hospitalizations, m (sd)	35	4.4 (4.2)	3.1 (1.4)	3.3 (3.3)	3.3 (2.6)	7.7 (6.2)	3.01	.045
<b>_</b> ·								
Regression		22 (54)	2 (20)		( (50)	0 (00)	7.0	0.47
Any Regression, n (%)	41	22 (54)	3 (30)	4 (44)	6 (50)	9 (90)	7.9	.047
Age at Regression, m (sd)	17	7.2 (6.1)	2.1 (2.7)	1.8 (1.6)	9.2 (3.2)	11 (7.2)	3.76	.038
Type of Regression, n (%)		4 (10)	<b>a</b> ( <b>a</b> )	2 (22)	a (a)			
Social Skills	39	4 (10)	0 (0)	3 (33)	0 (0)	1 (11)	7.6	.055+
Eating	40	11 (28)	2 (20)	2 (22)	3 (30)	4 (36)	.87	.832
Speech	40	9 (23)	0 (0)	3 (33)	I (9)	5 (45)	7.7	.053+
Motor	41	13 (32)	I (10)	3 (33)	3 (25)	6 (60)	6.1	.105
Adaptive Functioning and	Beha	vior						
Irritability (ABC) (sd)	31	4.7 (6.6)	3.3 (4.7)	9.2 (12)	4.8 (6.1)	3.6 (5.0)	.972	.420
Hyperactivity (ABC) (sd)	27	22 (15)	24 (13)	30 (11)	23 (17)	12 (12)	1.89	.159
Adaptive Functioning	31	35 (13)	49 (10)	46 (6.9)	28 (2.6)	24 (4.2)	30.82	<.0005
(VABS-2) (sd)								
Communication (VABS-2)	31	34 (10.6)	46 (11)	42 (5)	30 (1.2)	25 (3.2)	22.2	<.001
(sd)								
Social (VABS-2) (sd)	31	43 (14)	58 (10)	53 (5.8)	36 (4.5)	31 (11)	18.5	<.001
Daily Living (VABS-2) (sd)	31	35 (12)	46 (11)	45 (7.5)	29 (3.4)	24 (2.5)	22.7	<.001

CS: Christianson syndrome

GERD: gastroesophageal reflux disease

Values with + indicates numbers approaching statistical significance.

VABS-2: Vineland Adaptive Behavior Scales-Second Edition; the Adaptive Function score is a composite of the communication, daily living skills, socialization, and motor skills domain scores

ABC: Aberrant Behavior Checklist, a parent questionnaire to assess behavioral problems in individuals with developmental disorders

Domains presented in italics represent proposed core CS symptoms by age group

Table 3.				
Core Symptom (>85%)	<b>Toddlers</b> (2.5-5 years)	Children (6-11 years)	Adolescents (12-16 years)	Adults (17-32 years)
Nonverbal	✓	✓	1	1
Intellectual Disability	✓	✓	1	1
Epilepsy	✓	✓	1	1
Microcephaly		✓	1	1
Ataxia		✓	1	1
Hyperkinesia	✓	1	1	
High Pain Tolerance		✓	1	✓

#### 562 563

#### Supplemental Table I. Clinical Characteristics of CS Males by Inheritance and Mutation Type

	De Novo	Inherited	t/X2	Missense	Nonsense	t/X <sup>2</sup>
	(n = 15)	(n = 22)	Þ	(n = 6)	(n = 22)	Þ
General						
Age at Enrollment (sd)	12 (5.9)	13 (7.8)	.603	8.1 (6.6)	14 (5.8)	.041
Age at CS Diagnosis, m (sd)	7.1 (5.7)	8.6 (7.6)	.523	6.1 (4.5)	8.5 (6.7)	.403
Able to Walk Currently (%)	11 (85)	17 (81)	.785	5 (83)	16 (76)	.959
History of Regression (%)	7 (54)	11 (52)	.934	2 (40)	11 (52)	.619
Neurological, n (%)						
Microcephaly	14 (100)	19 (95)	.396	5 (100)	20 (100)	-
Ataxia	14 (100)	17 (94)	.370	6 (100)	17 (94)	.555
Autism Spectrum Disorder	4 (29)	2 (10)	.162	l (17)	5 (25)	.671
Hyperkinesia	14 (100)	19 (86)	.149	3 (100)	18 (75)	.326
Prior Angelman Dx	4 (29)	8 (38)	.561	2 (33)	7 (35)	.940
High Pain Tolerance	14 (100)	19 (86)	.149	6 (100)	19 (90)	.432
Unprovoked Laughter	6 (43)	16 (76)	.046	4 (67)	14 (70)	.877
Contractures	5 (36)	5 (28)	.631	2 (40)	5 (28)	.599
Visual Acuity Problems	9 (64)	9 (43)	.214	4 (67)	10 (50)	.473
Eye Movement Abnormalities	9 (69)	14 (70)	.963	3 (60)	14 (74)	.549
Medical Status, n (%)						
Swallowing Problems	7 (100)	8 (36)	.418	3 (50)	8 (38)	.601
GERD	8 (57)	11 (52)	.782	3 (50)	11 (55)	.829
Current Constipation	5 (42)	13 (62)	.261	4 (67)	11 (61)	.808
Osteopenia	2 (14)	0 (0)	.089	I (17)	I (6)	.394
Current Sleep Problems	6 (43)	12 (55)	.494	3 (50)	11 (52)	.918
Frequent Infections	3 (23)	5 (24)	.961	3 (50)	3 (16)	.087
# of Hospitalizations, m (sd)	3.9 (2.7)	5.0 (5.4)	.521	3.2 (1.5)	4.4 (3.8)	.570
Adaptive Functioning and Behavior						
VABS-2: Adaptive Function	35 (13)	34 (14)	.839	40 (12.5)	30 (9.4)	.082
ABC: Irritability	6.0 (6.3)	4.9 (7.4)	.704	5 (7.8)	4.6 (5.6)	.920
ABC: Hyperactivity	31 (6.0)	21 (16)	.136	35 (11.8)	21.6 (13.6)	.135

VABS-2: Vineland Adaptive Behavior Scales-Second Edition; the Adaptive Function score is a composite of the communication, daily living skills, socialization, and motor skills domain scores

ABC: Aberrant Behavior Checklist, a parent questionnaire to assess behavioral problems in individuals with developmental disorders

GERD: gastroesophageal reflux disease

565	Supplemental Table 2. Neurological Exams on 12 CS Male	s
-----	--	---

Age @ Exam	Mutation cDNA position	Mutation Protein Position	Vocalizations	Extraocula r Movement s	Tone, limb or side	Strength, or pattern of weakness	Tremor	Deep tendon reflex (DTR)	Babinski, left or right	Gait: base, posture
6-10	c.1380_13 89delinsG TCTTGG GAAGAC T	p.N460Kf s*I2	Present	Esotropia, L>R	Normal	Full	None	Normal and symmetric	Absent	Wide base
11-15	c.680+5G >A	-	Present	Esotropia, s.p. surgical correction	Normal	Full	None	Could not assess	Could not assess	Wide base
11-15	c.899+1de IGTAA	-	Present	Esotropia, L	Could not assess	Full	None	Normal and symmetric	B/L	Unable to walk
11-15	c.680+1G >A	-	~ 5 words	Normal	Normal	Full	None	Normal and symmetric	Absent	Normal
16-20	c.526-1>A	-	Present	Strabismus, s.p. surgical correction	Low- normal	Could not assess	None	High amplitude patellar reflexes with crossed- adductor response	Right	Wide base
16-20	c.630_631 insT	p.I211Yfs* 53	Present	Strabismus, s.p. incomplete surgical correction	Low- normal	Full	Upper extremity action tremor	High amplitude throughout	Left	Wide base
21-25	c.540_547 dup	p.F183fs*1	Present	Normal	Increased tone, R>L	Full	Left arm intermitte nt postural tremor	Normal and symmetric	Absent	Wide base
21-25	120.7kb deletion from intron 10 through 3'- untranslat od rogion	-	Present	Normal	Increased tone, L>R	Mild Left hemiparesis	None	Normal and symmetric	Left	Posturin g of upper extremiti es
26-30	c.630_631 insT	p.1211Yfs* 53	Present	Normal	Increased tone, Left leg	Full	None	High amplitude throughout; symmetric	B/L	Wide base with toe walking
26-30	c.1148G> A	p.G383D	Present	Normal	Normal	Full	None	Normal and symmetric	Absent	Wide base
26-30	c.1569G> A	p.W523*	Present	Normal	Normal	Full	Left leg tremor	Normal and symmetric	Unable to assess	Wide base
26-30	c.630_631 insT	p.1211Yfs* 53	Present	Strabismus, s.p. surgical correction	Increased tone	Full	Upper extremity action tremor	High amplitude throughout	B/L	Wide base, diminish ed arm swing

566 L=Left. R=Right. L>R=Left greater than right. R>L=Right greater than left. s.p.=status post.